1. Home
  2. SNDX vs TV Comparison

SNDX vs TV Comparison

Compare SNDX & TV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • TV
  • Stock Information
  • Founded
  • SNDX 2005
  • TV 1969
  • Country
  • SNDX United States
  • TV Mexico
  • Employees
  • SNDX N/A
  • TV N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • TV Broadcasting
  • Sector
  • SNDX Health Care
  • TV Industrials
  • Exchange
  • SNDX Nasdaq
  • TV Nasdaq
  • Market Cap
  • SNDX 1.1B
  • TV 1.2B
  • IPO Year
  • SNDX 2016
  • TV 1993
  • Fundamental
  • Price
  • SNDX $9.34
  • TV $2.11
  • Analyst Decision
  • SNDX Strong Buy
  • TV Buy
  • Analyst Count
  • SNDX 11
  • TV 4
  • Target Price
  • SNDX $34.00
  • TV $3.87
  • AVG Volume (30 Days)
  • SNDX 2.0M
  • TV 1.5M
  • Earning Date
  • SNDX 07-31-2025
  • TV 07-25-2025
  • Dividend Yield
  • SNDX N/A
  • TV 3.78%
  • EPS Growth
  • SNDX N/A
  • TV N/A
  • EPS
  • SNDX N/A
  • TV N/A
  • Revenue
  • SNDX $43,722,000.00
  • TV $2,998,354,359.00
  • Revenue This Year
  • SNDX $431.08
  • TV N/A
  • Revenue Next Year
  • SNDX $105.38
  • TV N/A
  • P/E Ratio
  • SNDX N/A
  • TV N/A
  • Revenue Growth
  • SNDX N/A
  • TV N/A
  • 52 Week Low
  • SNDX $8.58
  • TV $1.55
  • 52 Week High
  • SNDX $25.07
  • TV $2.71
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 51.90
  • TV 43.77
  • Support Level
  • SNDX $8.59
  • TV $2.12
  • Resistance Level
  • SNDX $10.01
  • TV $2.37
  • Average True Range (ATR)
  • SNDX 0.51
  • TV 0.08
  • MACD
  • SNDX 0.15
  • TV -0.03
  • Stochastic Oscillator
  • SNDX 87.46
  • TV 0.00

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About TV Grupo Televisa S.A.

Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.

Share on Social Networks: